As the 6th issuance under this program, unsecured convertible bonds with warrants will be issued through a third-party allotment. Total issue amount is 187,200,000 yen, conversion price is 297.9 yen, interest rate 1.0%, maturity date November 22, 2029. Allottee is Cantor Fitzgerald Europe. Proceeds will be used for drug discovery R&D and working capital. Dilution is expected to be approximately 19.22% of total issued shares. The allottee allocation was resolved following a fair value assessment by an independent valuation institution.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4572","jir_company_name":"Carna Biosciences, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4572-20261109-01.pdf","jir_short_summary":"As the 6th issuance under this program, unsecured convertible bonds with warrants will be issued through a third-party allotment. Total issue amount is 187,200,000 yen, conversion price is 297.9 yen, interest rate 1.0%, maturity date November 22, 2029. Allottee is Cantor Fitzgerald Europe. Proceeds will be used for drug discovery R&D and working capital. Dilution is expected to be approximately 19.22% of total issued shares. The allottee allocation was resolved following a fair value assessment by an independent valuation institution.","jir_summary":"### Financing Highlights\nThis disclosure announces the resolution to issue the 6th unsecured convertible bonds with warrants by allotting them to Cantor Fitzgerald Europe, and the related allotment of warrants and new shares. The total amount is 187,200,000 yen, the conversion price is 297.9 yen, the interest rate is 1.0%, and the maturity date is November 22, 2029. The fair value assessment for the allottee was conducted by an independent third-party institution. Proceeds are planned to be allocated to drug discovery research and development and working capital, and dilution is expected to be approximately 19.22%.\n\n### Future Impact and Schedule\nThe allottee is Cantor Fitzgerald Europe. Detailed provisions and adjustment mechanisms related to conversion are established, and the exercise period is from 2026-11-26 to 2029-11-22. Issue terms will be finalized after a valuation report by Akasaka International Accounting to ensure fairness. The number of shares to be delivered upon the allottee's exercise and conversion is expected to be up to 1,893,986 shares, and voting rights are estimated at 18,939 units. The financing aims to continue supporting investment in drug discovery development and strengthen working capital.","jir_financial_highlights":"Total amount of these bonds with warrants: 187,200,000 yen (Unknown)\nConversion price: 297.9 yen (Unknown)\nInterest rate: Annual 1.0% (Unknown)\nMaturity date: 2029-11-22 (Unknown)\nPotential number of shares: 698,220 shares (third-party allotment of these bonds with warrants) (Unknown)\nOverall dilution rate: 19.22% (relative to total issued shares) (Unknown)","jir_category":"","jir_hashtags":"#CarnaBiosciences, #Fundraising, #BondsWithWarrants, #DrugDiscoveryInvestment","jir_key_figures":"Total principal of these bonds: 208,000,000 yen (payment amount: 90 yen per 100 yen subscription price)\nTotal number of warrants: 40 units\nPotential number of shares: 698,220 shares\nConversion price: 297.9 yen\nDilution: 19.22% (ratio to total issued shares)","jir_meta_title":"Carna Biosciences, Inc. Announces Resolution to Allot 6th Bonds with Warrants via Third-Party Allotment\uff5cSecuring Drug Discovery Funding","jir_meta_description":"Carna Biosciences, Inc. has resolved to issue the 6th unsecured convertible bonds with warrants, allotted to Cantor Fitzgerald Europe. Conversion price is 297.9 yen, maturity date is 2029-11-22. Proceeds will be used for drug discovery R&D and working capital. Estimated dilution approximately 19.22%.","jir_og_title":"Carna Biosciences, Inc. Resolves 6th Third-Party Allotment of Bonds with Warrants\uff5cSecuring Drug Discovery Funding","jir_og_description":"Announced resolution to allot the 6th bonds with warrants to Cantor Fitzgerald Europe. Conversion price 297.9 yen, maturity 2029-11-22, estimated dilution ~19.22%. Proceeds to be used for drug discovery R&D and working capital.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59427,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-145817","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n